هوفمان-لا روش
Coordinates: 47°33′31″N 7°36′22″E / 47.558624°N 7.606018°E
F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
 | |
 The Roche Tower, headquarters of Hoffmann-La Roche in Basel (2015). | |
| النوع | Aktiengesellschaft |
|---|---|
| رمز التداول | SIX: ROG |
| ISIN | CH0012032113  |
| الصناعة | Pharmaceuticals |
| تأسست | 1896 |
| المؤسس | Fritz Hoffmann-La Roche |
| المقر الرئيسي | Basel, Switzerland |
الأشخاص الرئيسيون |
|
| المنتجات | Pharmaceuticals and diagnostics (List of products) |
| الدخل | 56.846 billion Swiss francs (CHF) (2018)[4] |
| ربح العمليات | CHF 14.769 billion (2018) |
| CHF 10.865 billion (2018)[4] | |
| إجمالي الأصول | CHF 78.517 billion (2018)[4] |
| إجمالي الأنصبة | CHF 30.366 billion (2018)[4] |
| الموظفون | 94,442 (2018)[4] |
| الشركة الأم | Roche Holding AG |
| الشركات التابعة | Genentech, Ventana |
| الموقع الإلكتروني | www |
The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based Ventana. Roche's revenues during fiscal year 2018 were 56.85 billion Swiss francs,[4] or approximately US$57 billion. Roche is the second-largest pharmaceutical company worldwide.[5] Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares. Roche is one of the few companies increasing their dividend every year, for 2018 as the 32nd consecutive year.[4] F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[6]
قادة العالم وضمنهم كوفي عنان أمين عام الأمم المتحدة أعربوا عن رغبتهم في وجود بدائل عامة لمصل أنفلونزا الطيور، تاميفلو، بسعر رخيص لدول العالم الثالث التي لن تقدر على شراء الدواء الأصلي.
وفي سابقة في 20 أكتوبر 2005 قررت روش ترخيص مصنعين آخرين لإنتاج أوسلتافيمير
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Financial data
| Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 46.780 | 47.462 | 48.145 | 50.576 | 53.299 | 56.846 |
| Net Income | 11.164 | 9.332 | 8.863 | 9.576 | 8.633 | 10.865 |
| Assets | 62.167 | 75.641 | 75.763 | 76.819 | 76.676 | 78.517 |
| Employees | 85,080 | 88,509 | 91,747 | 94,052 | 93,734 | 94,442 |
Products
 | هذا section يحتاج المزيد من الأسانيد للتحقق. (January 2020) (Learn how and when to remove this template message) |
Hoffmann-La Roche is strong in the field pharmaceuticals for cancer treatment, against virus diseases and for treatment of metabolic diseases. The company is the world's largest spender in pharmaceutical R&D.[8]
Drugs produced by Roche include:[معلومات قديمة][original research?][بحاجة لمصدر]
- Accutane/RoAccutane (isotretinoin), for severe (nodular) acne vulgaris - no longer sold under Accutane brand name but is still available as RoAccutane, other brand names and Isotretinoin generics.[9]
- Actemra/RoActemra (tocilizumab), for rheumatoid arthritis.
- Actimmune (interferon gamma), for chronic granulomatous disease, later sold to Connetics Corporation, then InterMune, after that Vidara Therapeutics and finally Horizon Pharma as of 2019.
- Activase (alteplase), for heart attacks.
- Akynzeo (netupitant/palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
- Alecensa (alectinib), for ALK-positive non-small cell lung cancer.
- Aloxi (palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics.
- Anexate (flumazenil), for the reversal of acute benzodiazepine effects.
- Aurorix (moclobemide), for depression.
- Avastin (bevacizumab), for certain malignant tumors.
- Bactrim (trimethoprim/sulfamethoxazole), a sulphonamide antibacterial.
- Boniva/Bonviva (ibandronic acid), for the treatment of osteoporosis in postmenopausal women.
- Camleed (enprostil), for gastric ulcer prevention.
- Cardene (nicardipine), for treatment of stable angina pectoris.
- Cathflo Activase (alteplase), for heart attacks.
- Cellcept (mycophenolate mofetil), for transplant rejection.
- Cotellic (cobimetinib), for melanoma.
- Cymevene (ganciclovir), for cytomegalovirus infection.
- Dalmane/Dalmadorm (flurazepam), for insomnia.
- Dilatrend (carvedilol), for hypertension and congestive heart failure.
- Dormicum (midazolam), for insomnia and procedural sedation and analgesia.
- Erivedge (vismodegib), for basal-cell carcinoma.
- Esbriet (pirfenidone), for idiopathic pulmonary fibrosis.
- Fansidar (sulfadoxine/pyrimethamine), for malaria and toxoplasmosis.
- Fuzeon (enfuvirtide), for salvage therapy of HIV-1 infection.
- Gazyva (obinutuzumab), for chronic lymphocytic leukemia.
- Hemlibra (emicizumab), for haemophilia A.
- Herceptin (trastuzumab), for HER-2 positive breast cancer.
- Hivid (zalcitabine), for HIV-1 infection, later discontinued in 2006.
- Inhibace (cilazapril), for hypertension and congestive heart failure.
- Invirase (saquinavir), for HIV-1 infection.
- Kadcyla (trastuzumab emtansine), for HER-2 positive breast cancer.
- Klonopin/Rivotril (clonazepam), for epilepsy and anxiety disorders.
- Kytril (granisetron), for chemotherapy-induced nausea and vomiting, licensed by GlaxoSmithKline.
- Lariam (mefloquine), for malaria (both prevention and treatment).
- Lexotanil (bromazepam), for anxiety disorders.
- Lucentis (ranibizumab), for wet age-related macular degeneration (AMD).
- Luxturna (voretigene neparvovec), for Leber's congenital amaurosis.
- MabThera (rituximab), for B-cell chronic lymphocytic leukemia (and other hematological malignancies), non-Hodgkin lymphomas and rheumatoid arthritis.
- Madopar/Prolopa (levodopa/benserazide), for Parkinson's disease.
- Mircera (methoxy polyethylene glycol-epoetin beta), for anaemia associated with chronic kidney disease.
- Naprosyn (naproxen), an NSAID used for pain relief and arthritis treatment.
- Neulastim (pegfilgrastim), for neutropenia.
- Neupogen (filgrastim), for neutropenia.
- Nutropin (somatropin), for growth hormone deficiency.
- Nutropin AQ (somatropin), for growth hormone deficiency.
- Nutropin Depot (somatropin), for growth hormone deficiency, later discontinued in 2004 and replaced by Nutropin AQ.
- Ocrevus (ocrelizumab), for MS.
- Pegasys, (peginterferon alfa-2a) for hepatitis B and C.
- Perjeta (pertuzumab), for HER-2 positive breast cancer.
- Polivy (polatuzumab vedotin), for diffuse large B-cell lymphoma.
- Protropin (somatrem), for growth hormone deficiency, later discontinued in 2004 in favor of its successor, Nutropin.
- Pulmozyme (dornase alfa), for the improvement of pulmonary function in cystic fibrosis.
- Raptiva (efalizumab), for psoriasis, later withdrawn in 2009 due to the risk of PML.
- Recormon/NeoRecormon (epoetin beta), for anemia.
- Rituxan (rituximab), for non-Hodgkin's lymphoma.
- Rocaltrol (calcitriol), for osteoporosis and hypocalcaemia.
- Rocephin (ceftriaxone), a broad-spectrum cephalosporin antibiotic.
- Roferon A (peginterferon alfa-2a), for some hematological malignancies (hairy cell leukemia, chronic myelogenous leukemia), certain solid tumors (including Kaposi's sarcoma), genital warts and chronic hepatitis C.
- Rohypnol (flunitrazepam), for severe insomnia.
- Rozlytrek (entrectinib), for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.
- Soriatane/Neotigason (acitretin), for psoriasis.
- Tamiflu (oseltamivir), for influenza A and B (both treatment and prevention).
- Tarceva (erlotinib), for various cancers.
- Tasmar (tolcapone), for parkinson's disease, licensed by Mylan and Bausch Health.
- Tecentriq (atezolizumab), for non-small cell lung cancer.
- TNKase (tenecteplase), for heart attacks.
- Toradol (ketorolac), for pain management.
- Valcyte (valganciclovir), for cytomegalovirus infection.
- Valium (diazepam), for anxiety disorders, alcohol withdrawal, status epilepticus and other conditions.
- Venclexta (venetoclax), for chronic lymphocytic leukemia.
- Versed (midazolam), for insomnia and procedural sedation and analgesia.
- Vesanoid (tretinoin), for acute promyelocytic leukemia.
- Viracept (nelfinavir), for HIV-1 infection, licensed by Pfizer and ViiV Healthcare.
- Xeloda (capecitabine), for breast and colorectal cancer.
- Xenical (orlistat), for obesity.
- Xofluza (baloxavir marboxil), for influenza A and B (both treatment and prevention).
- Xolair (omalizumab), for asthma.
- Zelboraf (vemurafenib), for late-stage V600E BRAF mutation-positive melanoma.
- Zenapax (daclizumab), for the prevention of acute transplant rejection.
Diabetes management products produced by Roche under the Accu-Chek brand include Accu-Chek Mobile, Accu-Chek Aviva, Accu-Chek Compact Plus, Accu-Chek Aviva Expert, Accu-Chek Active, Accu-Chek Advantage, Accu-Chek Performa, Accu-Chek Aviva Nano, Accu-Chek Performa Nano blood glucose monitors. Accu-Chek Spirit and Accu-Chek Combo insulin pumps. Accu-Chek 360 and SmartPix diabetes management software.
Other products include:
Price-fixing conspiracy
Stanley Adams, Roche's World Product Manager in Basel, contacted the European Economic Community in 1973 with evidence that Roche had been breaking antitrust laws, engaging in price fixing and market sharing for vitamins with its competitors. Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. He was arrested for unauthorised disclosure — an offence under Swiss law — and imprisoned. His wife, having learnt that he might face decades in jail, committed suicide.[10]
In 1999 the firm pleaded guilty to participation in a worldwide conspiracy to raise and fix prices for vitamins sold in the US and globally. Hoffmann-La Roche paid $500 million in criminal fines to the United States.[10][11][12]
Collaborative research
In addition to internal research and development activities F. Hoffmann-La Roche is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[13][14] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[15]
See also
References
- ^ "Executive Committee". Roche.com. F. Hoffmann-La Roche. Archived from the original on 14 September 2016. Retrieved 26 November 2016.
- ^ "Roche names new head of $13 billion diagnostics unit". Reuters. 11 June 2019.
- ^ "FDA Grants Roche Breakthrough Therapy Designation on Hemophilia Drug". BioPharm International. UBM. 19 April 2018. Retrieved 2018-04-20.
- ^ أ ب ت ث ج ح خ "Financial Report 2018" (PDF). Roche Holding. Retrieved 1 February 2019.
- ^ "Roche reports a strong start in 2019 and raises the outlook for the full-year".
- ^ "The Pharmaceutical Industry in Figures – 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 سبتمبر 2008. Retrieved 25 أغسطس 2008.
- ^ "Roche Holding Bilanz, Gewinn und Umsatz | Roche Holding Geschäftsbericht | 855167". wallstreet-online.de. Retrieved 2018-11-05.
- ^ Miller, John (19 December 2017). "Roche touts Swiss-led R&D unit after years in Genentech's shadow". Reuters. Retrieved 19 December 2017.
- ^ "Roche stops selling acne drug Accutane". Reuters. 2009-06-26. Retrieved 2016-02-23.
- ^ أ ب Mathiason, Nick (25 November 2001). "Blowing the final whistle". The Observer. Retrieved 30 September 2014.
- ^ Corporate Crime Reporter. Corporate Crime Reporter. Retrieved on 2013-11-24.
- ^ "Cartel price announcements: The vitamins industry" (PDF). International Journal of Industrial Organization. 26. 2008.
- ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- ^ "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.
- ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 أكتوبر 2009. Retrieved 25 أغسطس 2008.
Further reading
- Hans Conrad Peyer (1996) Roche – A Company History 1896–1996 Basel: Editiones Roche ISBN 3-907770-59-5